Literature DB >> 15685092

[Readability of informed consent forms for subjects participating in biomedical research: updating is required].

A Paris1, J-L Cracowski, N Ravanel, C Cornu, F Gueyffier, B Deygas, K Guillot, J-L Bosson, M Hommel.   

Abstract

OBJECTIVE: We compared informed consent forms of subjects participating in biomedical research with those of references texts in order to determine the factors that influence readability.
METHODS: We assessed the readability of 73 informed consent forms of research protocols conducted in the clinical investigation centres in the Rhone-Alpes area, and then compared them with 33 reference texts corresponding to 5 French school grades (first year infant, primary school, GCS level, high school, and classics aggregation), using the Flesch test and Cordial" analyser.
RESULTS: Median Flesch scores were 66 for the first year infant level, 62 for the primary school level, 58 for the GCS level, 42 for the high school level, and 43 for the aggregation level. It was 22 for the informed consent forms. Median Cordial scores were 86 for the first year infant level, 77 for the second, 74 for the third, 49 for the fourth, 43 for the fifth. It was 1 for the informed consent forms. No methodological factor correlated with Flesch and Cordial" results.
CONCLUSION: The quantitative readability scores for informed consent forms for subjects participating in biomedical research are low, lower than those proposed to aggregation candidates, whatever the type of protocol. Some thought must be given to the impact of the reduced readability on patients' understanding, and steps should be taken to improve the readability of the forms.

Entities:  

Mesh:

Year:  2005        PMID: 15685092     DOI: 10.1016/s0755-4982(05)83877-1

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  7 in total

1.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher
Journal:  BMJ       Date:  2013-01-08

2.  Improved informed consent documents for biomedical research do not increase patients' understanding but reduce enrolment: a study in real settings.

Authors:  Adeline Paris; Béatrice Deygas; Catherine Cornu; Claire Thalamas; Patrick Maison; Christian Duale; Maty Kane; Enkelejda Hodaj; Jean-Luc Cracowski
Journal:  Br J Clin Pharmacol       Date:  2015-09-21       Impact factor: 4.335

3.  Informed consent document improvement does not increase patients' comprehension in biomedical research.

Authors:  Adeline Paris; Christian Brandt; Catherine Cornu; Patrick Maison; Claire Thalamas; Jean-Luc Cracowski
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

4.  The readability of information and consent forms in clinical research in France.

Authors:  Véronique Ménoni; Noël Lucas; Jean François Leforestier; Jérôme Dimet; François Doz; Gilles Chatellier; Jean-Marc Tréluyer; Hélène Chappuy
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

5.  Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patients.

Authors:  Tanguy Leroy; Véronique Christophe; Nicolas Penel; Pascal Antoine; Stéphanie Clisant
Journal:  Invest New Drugs       Date:  2009-09-18       Impact factor: 3.850

6.  Readability of the written study information in pediatric research in France.

Authors:  Véronique Ménoni; Noël Lucas; Jean-François Leforestier; François Doz; Gilles Chatellier; Evelyne Jacqz-Aigain; Carole Giraud; Jean-Marc Tréluyer; Hélène Chappuy
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

7.  Mapping health literacy research in the European Union: a bibliometric analysis.

Authors:  Barbara K Kondilis; Ismene J Kiriaze; Anastasia P Athanasoulia; Matthew E Falagas
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.